These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 29378962)

  • 21. Molecular design and anticancer activities of small-molecule monopolar spindle 1 inhibitors: A Medicinal chemistry perspective.
    Wang S; Zhang M; Liang D; Sun W; Zhang C; Jiang M; Liu J; Li J; Li C; Yang X; Zhou X
    Eur J Med Chem; 2019 Aug; 175():247-268. PubMed ID: 31121430
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of the First Covalent Monopolar Spindle Kinase 1 (MPS1/TTK) Inhibitor.
    M Serafim RA; da Silva Santiago A; Schwalm MP; Hu Z; Dos Reis CV; Takarada JE; Mezzomo P; Massirer KB; Kudolo M; Gerstenecker S; Chaikuad A; Zender L; Knapp S; Laufer S; Couñago RM; Gehringer M
    J Med Chem; 2022 Feb; 65(4):3173-3192. PubMed ID: 35167750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTK.
    Laufer R; Li SW; Liu Y; Ng G; Lang Y; Feher M; Brokx R; Beletskaya I; Hodgson R; Mao G; Plotnikova O; Awrey DE; Mason JM; Wei X; Lin DC; Che Y; Kiarash R; Madeira B; Fletcher GC; Mak TW; Bray MR; Pauls HW
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3562-6. PubMed ID: 27335255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Understanding inhibitor resistance in Mps1 kinase through novel biophysical assays and structures.
    Hiruma Y; Koch A; Hazraty N; Tsakou F; Medema RH; Joosten RP; Perrakis A
    J Biol Chem; 2017 Sep; 292(35):14496-14504. PubMed ID: 28726638
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective inhibition of pancreatic ductal adenocarcinoma cell growth by the mitotic MPS1 kinase inhibitor NMS-P715.
    Slee RB; Grimes BR; Bansal R; Gore J; Blackburn C; Brown L; Gasaway R; Jeong J; Victorino J; March KL; Colombo R; Herbert BS; Korc M
    Mol Cancer Ther; 2014 Feb; 13(2):307-315. PubMed ID: 24282275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tank Binding Kinase 1 modulates spindle assembly checkpoint components to regulate mitosis in breast and lung cancer cells.
    Maan M; Agrawal NJ; Padmanabhan J; Leitzinger CC; Rivera-Rivera Y; Saavedra HI; Chellappan SP
    Biochim Biophys Acta Mol Cell Res; 2021 Mar; 1868(3):118929. PubMed ID: 33310066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic and pharmacological inhibition of TTK impairs pancreatic cancer cell line growth by inducing lethal chromosomal instability.
    Stratford JK; Yan F; Hill RA; Major MB; Graves LM; Der CJ; Yeh JJ
    PLoS One; 2017; 12(4):e0174863. PubMed ID: 28380042
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer.
    Jin J; Fang H; Yang F; Ji W; Guan N; Sun Z; Shi Y; Zhou G; Guan X
    Neoplasia; 2018 May; 20(5):478-488. PubMed ID: 29605721
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual TTK/CLK2 inhibitor, CC-671, selectively antagonizes ABCG2-mediated multidrug resistance in lung cancer cells.
    Wu ZX; Yang Y; Wang G; Wang JQ; Teng QX; Sun L; Lei ZN; Lin L; Chen ZS; Zou C
    Cancer Sci; 2020 Aug; 111(8):2872-2882. PubMed ID: 32478948
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A unique hinge binder of extremely selective aminopyridine-based Mps1 (TTK) kinase inhibitors with cellular activity.
    Kusakabe K; Ide N; Daigo Y; Itoh T; Yamamoto T; Kojima E; Mitsuoka Y; Tadano G; Tagashira S; Higashino K; Okano Y; Sato Y; Inoue M; Iguchi M; Kanazawa T; Ishioka Y; Dohi K; Kido Y; Sakamoto S; Ando S; Maeda M; Higaki M; Yoshizawa H; Murai H; Nakamura Y
    Bioorg Med Chem; 2015 May; 23(9):2247-60. PubMed ID: 25801152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of novel MPS1 inhibitors with preclinical anticancer activity.
    Jemaà M; Galluzzi L; Kepp O; Senovilla L; Brands M; Boemer U; Koppitz M; Lienau P; Prechtl S; Schulze V; Siemeister G; Wengner AM; Mumberg D; Ziegelbauer K; Abrieu A; Castedo M; Vitale I; Kroemer G
    Cell Death Differ; 2013 Nov; 20(11):1532-45. PubMed ID: 23933817
    [TBL] [Abstract][Full Text] [Related]  

  • 32. APC/C Dysfunction Limits Excessive Cancer Chromosomal Instability.
    Sansregret L; Patterson JO; Dewhurst S; López-García C; Koch A; McGranahan N; Chao WCH; Barry DJ; Rowan A; Instrell R; Horswell S; Way M; Howell M; Singleton MR; Medema RH; Nurse P; Petronczki M; Swanton C
    Cancer Discov; 2017 Feb; 7(2):218-233. PubMed ID: 28069571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TTK Inhibitors as a Targeted Therapy for
    Zaman GJR; de Roos JADM; Libouban MAA; Prinsen MBW; de Man J; Buijsman RC; Uitdehaag JCM
    Mol Cancer Ther; 2017 Nov; 16(11):2609-2617. PubMed ID: 28751540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TTK inhibitor promotes radiosensitivity of liver cancer cells through p21.
    Zhang H; Yao W; Zhang M; Lu Y; Tang J; Jiang M; Mou X; You G; Liang X
    Biochem Biophys Res Commun; 2021 Apr; 550():84-91. PubMed ID: 33689884
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutant p53 dictates the oncogenic activity of c-Abl in triple-negative breast cancers.
    Morrison CD; Chang JC; Keri RA; Schiemann WP
    Cell Death Dis; 2017 Jun; 8(6):e2899. PubMed ID: 28661474
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel Mps1 kinase inhibitors: from purine to pyrrolopyrimidine and quinazoline leads.
    Bursavich MG; Dastrup D; Shenderovich M; Yager KM; Cimbora DM; Williams B; Kumar DV
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6829-33. PubMed ID: 24183538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure-Guided Optimization Provides a Series of TTK Protein Inhibitors with Potent Antitumor Activity.
    Elsner J; Cashion D; Robinson D; Bahmanyar S; Tehrani L; Fultz KE; Narla RK; Peng X; Tran T; Apuy J; LeBrun L; Leftheris K; Boylan JF; Zhu D; Riggs JR
    J Med Chem; 2021 Sep; 64(17):12670-12679. PubMed ID: 34459599
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systems Biology Modeling of Five Pathways for Regulation and Potent Inhibition of the Anaphase-Promoting Complex (APC/C): Pivotal Roles for MCC and BubR1.
    Ibrahim B
    OMICS; 2015 May; 19(5):294-305. PubMed ID: 25871779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bub1 and aurora B cooperate to maintain BubR1-mediated inhibition of APC/CCdc20.
    Morrow CJ; Tighe A; Johnson VL; Scott MI; Ditchfield C; Taylor SS
    J Cell Sci; 2005 Aug; 118(Pt 16):3639-52. PubMed ID: 16046481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CFI-402257, a TTK inhibitor, effectively suppresses hepatocellular carcinoma.
    Chan CY; Chiu DK; Yuen VW; Law CT; Wong BP; Thu KL; Cescon DW; Soria-Bretones I; Cheu JW; Lee D; Tse AP; Zhang MS; Tan KV; Ng IO; Khong PL; Yau TC; Bray MR; Mak TW; Wong CC
    Proc Natl Acad Sci U S A; 2022 Aug; 119(32):e2119514119. PubMed ID: 35914158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.